Menu
Search
|

Menu

Close
X

ARMO Biosciences Inc ARMO.OQ (NASDAQ Stock Exchange Global Select Market)

48.01 USD
-- (--)
As of Feb 22
chart
Previous Close 48.01
Open --
Volume --
3m Avg Volume --
Today’s High --
Today’s Low --
52 Week High 57.00
52 Week Low 27.00
Shares Outstanding (mil) 28.41
Market Capitalization (mil) 1,364.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.272
FY16
-0.411
FY15
-0.219
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
--
8.08
Price to Book (MRQ)
vs sector
--
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
-89.84
13.67
Return on Equity (TTM)
vs sector
--
15.40

EXECUTIVE LEADERSHIP

Peter Vlasselaer
President, Chief Executive Officer, Founder, Director, Since
Salary: --
Bonus: --
Martin Oft
Founder and Vice President - Pre-Clinical and Clinical Development, Since
Salary: --
Bonus: --
Russell Kawahata
Vice President - Technical Operations, Since
Salary: --
Bonus: --
Scott Ogg
Vice President - Corporate Development and Operations, Since
Salary: --
Bonus: --
Gail Brown
Chief Medical Officer, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

575 Chesapeake Dr
REDWOOD CITY   CA   94063-4724

Phone: +1650.7795075

ARMO Biosciences, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients. The Company's has pipeline with an anti-Programmed Cell Death Protein 1 (PD-1) checkpoint inhibitor and therapeutic cytokines. The Company develops pipeline products to use in combination with AM0010, which include AM0015, a Recombinant human Interleukin-15 and AM0012, a Recombinant human Interleukin-12 (AM0012). The Company pipeline also includes AM0001 (anti-PD-1), which is a combination of anti-Programmed Cell Death Protein 1 (PD-1) checkpoint inhibitor and AM0010.

SPONSORED STORIES